Chronic hives (CSU) medication assistance in 2026: Xolair, Dupixent and Rhapsido programmes
Three medicines name chronic spontaneous urticaria on their own sites. Their copay offers all exclude Medicare and Medicaid, only one prints a bridge, and the foundation fund that covers all three is closed. Here is the door for each insurance type.
Three medicines carry a US chronic hives (CSU) label on their own sites and each publishes a different slice of help: Xolair prints a $15,000 yearly copay limit, Rhapsido prints a free bridge of up to 24 months while a private insurer decides, and Dupixent prints neither; none of the three copay offers works with Medicare or Medicaid, and the one independent fund that lists all three (HealthWell, up to 500% of the poverty level, $4,000 maximum award) was closed to new patients on 26 October 2026.
Method: we read each sponsor's own savings, bridge and foundation pages and HealthWell's fund page on 26 October 2026 and recorded what each prints, and what it leaves out. How we built thisQuick answer: where can you get help paying for a chronic hives medicine?
Match your insurance to the door:
- Commercial insurance: use the maker's copay offer. Xolair's co-pay programme covers up to $15,000 a year for the drug; DUPIXENT MyWay and Rhapsido Co-Pay Plus both say as little as $0 per fill, with a yearly limit they do not print.
- Insurer slow or has denied it: only Rhapsido publishes a bridge, free for up to 24 months or until coverage is approved.
- Medicare, Medicaid, VA, TRICARE or no insurance: none of the three copay offers applies. Ask the maker's free-drug route: Genentech Patient Foundation (Xolair), DUPIXENT MyWay Patient Assistance Program, Novartis Patient Assistance Foundation (Rhapsido).
- Independent fund: HealthWell's urticaria fund was closed to new patients on 26 October 2026; sign up for its re-opening alert.
Which medicines carry a US chronic hives (CSU) label, and who makes them?
Chronic spontaneous urticaria (CSU) is the label term for chronic hives with no known trigger. Three medicines name it as a US use on their own brand sites as of 26 October 2026. Each label, as the brand site words it, applies to people whose hives are not controlled by antihistamines; whether a medicine is right for you is a question for your prescriber, and this page compares the cost-help programmes only.
| Medicine | Maker | CSU use, as the brand site states it | Brand page read |
|---|---|---|---|
| XOLAIR (omalizumab) | Genentech | People 12 years and older with CSU not controlled by H1 antihistamines | xolair.com |
| DUPIXENT (dupilumab) | Regeneron and Sanofi | CSU with hives not controlled by H1 antihistamines (age range listed on the site) | dupixent.com |
| RHAPSIDO (remibrutinib) | Novartis | Adults with CSU or symptomatic dermographism not controlled with antihistamine treatment. First FDA approval 30 September 2025 (Drugs@FDA) | rhapsido.com |
What do the copay offers cover, and who is excluded?
All three offers are for commercial (private) insurance only, and each excludes government coverage in its own terms. The yearly limit is where they differ: Xolair prints a dollar figure and the other two say a maximum applies without printing it.
| Programme | What it pays | Who is excluded | Phone (sponsor page) |
|---|---|---|---|
| XOLAIR Co-pay Program (Genentech) | Drug: as little as $0, up to $15,000 per calendar year. Injection: up to $1,500 per calendar year. Age 18 or older, or a caregiver manages the account. | Medicare (including Advantage and Medigap), Medicaid, VA, DoD, TRICARE; the injection offer is not valid in Massachusetts or Rhode Island | 866-422-2377 |
| DUPIXENT MyWay Copay Card (Regeneron and Sanofi) | As little as $0 per fill. "Subject to the program maximum per patient per calendar year"; the maximum is not printed on the page. | Medicaid, Medicare, VA, DOD, TRICARE and state pharmaceutical assistance programmes | 1-844-387-4936, option 1 |
| RHAPSIDO Co-Pay Plus (Novartis) | Pay as little as $0. Combined annual limit across the card and rebate; the figure is not printed. List price $4,521 per 30-day pack (60 tablets) as of 7 January 2026. | Medicare, Medicaid, TRICARE, VA, DoD or any other federal or state programme; patients not using insurance | 877-427-7436 |
How do you get each medicine free if you cannot pay for it?
Each maker runs its own free-drug door, and they follow different rules. Try them in this order.
Xolair. The Genentech Patient Foundation gives free Xolair to people without insurance, or with financial concerns, who meet its rules: uninsured patients with incomes under $150,000; insured patients whose plan does not cover Xolair, also under $150,000; and insured patients whose plan covers it but whose out-of-pocket maximum exceeds 7.5% of household income, within income guidelines. Add $25,000 for each person beyond four in the household. Both a patient consent form and a prescriber form are required, and the page says requests are processed within five business days of receiving both. The foundation's line is (888) 941-3331. Our Genentech Access Solutions guide covers the programme in more depth.
Dupixent. The DUPIXENT MyWay Patient Assistance Program is for people with no insurance, difficulty paying, or Medicare Part D, and Dupixent's site says it evaluates eligibility case by case with a case manager. It prints no income limit. Our Dupixent coverage guide covers plan-side questions.
Rhapsido. Rhapsido is on the Novartis Patient Assistance Foundation medication list. Novartis says the foundation helps people who are uninsured or have government insurance and cannot afford their out-of-pocket costs; a Medicare patient must also not qualify for Extra Help (the Low Income Subsidy). The pages we read print no dollar income limit; our income limits comparison records the figure from the programme dataset (400% of the poverty level, $63,840 for one person), checked 19 October 2026, and the foundation's number is 1-800-277-2254.
What if you have Medicare or Medicaid?
The three copay offers all exclude Medicare and Medicaid in their own terms, so a commercial copay card is not available to you. The routes that remain are the maker's free-drug door and, for Medicare, low-income help from Medicare itself; see our Medicare Extra Help guide. Coverage matters too: in CMS's September 2026 Part D file, Xolair and Dupixent were listed on all 328 formularies (for any use), and Rhapsido on 36.
Is the HealthWell urticaria fund open?
No. HealthWell's urticaria fund page read "Closed" on 26 October 2026, "temporarily closed to new patients due to lack of sufficient funding." When open it offers prescription copay help or Medicare Part B premium help, with a maximum award of $4,000 and a household income limit of 500% of the federal poverty level; its covered-treatment list names Dupixent, Xolair and Rhapsido and also generic antihistamines such as cetirizine and fexofenadine. A current grant stays active for its 12-month cycle. HealthWell requires some insurance that covers the medicine, and refers uninsured patients to manufacturer programmes. Our HealthWell guide lists its other funds.
What should you ask when you call?
Medicine: ______________ Insurance type: ______________ Date called: ________ Person spoken to: ________ Reference no.: ________ Commercial insurance: [ ] Does my plan cover this medicine, and is prior authorization required? [ ] Is the maker's copay offer open to me? What is the yearly limit? [ ] Is there a bridge if my insurer is slow or has denied it? (Rhapsido: up to 24 months) [ ] Do I have to file the prior authorization or appeal by a deadline to stay enrolled? Medicare, Medicaid, VA, TRICARE, or no insurance: [ ] Which free-drug programme covers this medicine, and what income limit applies? [ ] Which documents do you need (proof of income, a prescriber form)? [ ] Medicare patients: do I need a denial letter for Extra Help first? Numbers on the sponsors' own pages (26 Oct 2026): Xolair co-pay programme 866-422-2377 | Genentech Patient Foundation (888) 941-3331 DUPIXENT MyWay 1-844-387-4936, option 1 Novartis Patient Support (Rhapsido) 877-427-7436 | Novartis Patient Assistance Foundation 1-800-277-2254
What should you do, by situation?
- If you have commercial insurance and your prescriber has chosen one of the threeEnrol in that maker's copay offer first and ask what its yearly limit is. If the insurer is slow on Rhapsido, ask about the bridge before the first fill.
- If you have MedicareThe copay offers will not work for you. Ask the maker's free-drug door, check Extra Help eligibility first (Novartis asks for it), and ask your plan whether the medicine needs prior authorization.
- If you have no insuranceStart with the maker's foundation for the medicine your prescriber has chosen; Genentech's is the only one of the three that prints a household income line ($150,000 for one to four people).
- If you hoped for an independent grantThe HealthWell urticaria fund is closed today. Register for its re-opening alert and use a maker route meanwhile.
We read each programme's own eligibility page, application form or terms on 26 October 2026 (Xolair and the Genentech Patient Foundation, DUPIXENT MyWay, Rhapsido and Novartis Patient Support, the Novartis Patient Assistance Foundation medication list, HealthWell's urticaria fund page), converted dollar limits to percentages of the 2026 HHS poverty guideline where a percentage was needed, and drew on the OmniRx patient assistance dataset and CMS's September 2026 Part D formulary file for the formulary counts. We did not apply to any programme. Where a programme does not publish a figure, we say so rather than estimate it. OmniRx does not employ named credentialed reviewers; this is patient-navigation reference, not medical advice, and we do not compare how well the medicines work. Full policy.
Related: bridge programmes compared, every drugmaker's income limit and the assistance finder.
Frequently asked questions
Can I get Xolair, Dupixent or Rhapsido for free?
Possibly, through the maker's own free-drug route: the Genentech Patient Foundation for Xolair (uninsured patients under $150,000 household income, with other rules for insured patients), the DUPIXENT MyWay Patient Assistance Program (case by case, no published limit) and the Novartis Patient Assistance Foundation for Rhapsido. Eligibility is decided by each programme.
Do the chronic hives copay cards work with Medicare or Medicaid?
No. The Xolair co-pay programme, the DUPIXENT MyWay Copay Card and Rhapsido Co-Pay Plus each exclude Medicare and Medicaid, and also VA, DoD and TRICARE, in their own terms, as read on 26 October 2026.
Is the HealthWell urticaria fund open?
No. HealthWell's urticaria fund page read "Closed" on 26 October 2026, temporarily closed to new patients for lack of funding. When open it has a maximum award of $4,000 and a 500% federal poverty level income limit. Current grants stay active for their 12 months.
Does any chronic hives medicine publish a bridge for insurance delays?
Rhapsido does: if you have private insurance and coverage is delayed or denied, the Novartis Bridge Program provides it free for up to 24 months or until coverage is approved, provided a prior authorization or appeal is filed within 90 days of enrolment. Xolair's and Dupixent's pages we read publish no bridge.
What are the phone numbers to ask about cost help?
From the sponsors' own pages: Xolair co-pay programme 866-422-2377, Genentech Patient Foundation (888) 941-3331, DUPIXENT MyWay 1-844-387-4936 option 1, Novartis Patient Support for Rhapsido 877-427-7436 and the Novartis Patient Assistance Foundation 1-800-277-2254.
The bottom line
For chronic hives the first question is your insurance type: commercial insurance opens a maker copay offer (Xolair prints a $15,000 yearly limit; Dupixent and Rhapsido print none), while Medicare, Medicaid, VA and TRICARE close all three and leave the maker's free-drug foundation. Only Rhapsido publishes a bridge, and the HealthWell fund that covers all three was closed on 26 October 2026.
Sources
- Genentech. XOLAIR financial assistance options (co-pay programme and Patient Foundation). xolair.com checked 2026-10-26
- Genentech. XOLAIR for chronic spontaneous urticaria. xolair.com checked 2026-10-26
- Genentech. Genentech Patient Foundation. gene.com checked 2026-10-26
- Regeneron and Sanofi. DUPIXENT MyWay Copay Card and Patient Assistance Program. dupixent.com checked 2026-10-26
- Novartis. RHAPSIDO Savings and Support (Co-Pay Plus and Bridge Program). rhapsido.com checked 2026-10-26
- Novartis. Novartis Patient Assistance Foundation medication list. pap.novartis.com checked 2026-10-26
- HealthWell Foundation. Urticaria fund. healthwellfoundation.org checked 2026-10-26
- FDA. Drugs@FDA application data for RHAPSIDO (openFDA). api.fda.gov checked 2026-10-26
- HHS ASPE. 2026 poverty guidelines. aspe.hhs.gov checked 2026-10-26
- Centers for Medicare & Medicaid Services. Part D formulary file, contract year 2026 (September 2026). data.cms.gov (zip) checked 2026-10-04